Author(s)

Dehong Yin, Gaomiyang Liu, Fei Shi, Yijia Song, Rong Lu

Corresponding Author

Gaomiyang Liu

Abstract

Purpose: To analyze the dynamic evaluation and efficacy of ultra-high sensitivity chromosome instability detection in liver cancer treatment. Method: Randomly selected 72 patients with liver cancer from September 20 to May 2019 in our hospital and through various chemical methods, we have come to understand the expression of MSI and mutant P53 protein in chromosome 17P of patients with liver cancer. Outcome: It can be seen from the experiment that there is no difference between the MSI and the patient's gender (P>0.05). For the sudden P53 protein expression, there is no significant difference in each age of onset (P>0.05), but AFP is positive, because the positive expression rate of hepatoma mutant P53 protein was significantly higher than that of AFP negative liver cancer (P<0.05) and there was no significant difference between the expression of positive liver cancer mutant protein and negative (P>0.05), and there was also no comparability. Conclusion: There is no correlation between MSI and the pathogenesis of most HCC. The carcinogenic mechanism of P53 gene mutation in HCC does not pass the path of MSI pathology of the expression of P53 gene mutation will be different, and the difference in expression will be closely related to carcinogenic factors, so people should also gradually increase their research efforts to promote the treatment of the disease.

Keywords

Liver cancer, Ultra-high sensitivity chromosome, Instability test, Dynamic assessment, healing efficacy